Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 2633)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 11 AUGUST 2026; (2) PAYMENT OF FINAL DIVIDEND; AND (3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

POLL RESULTS OF ANNUAL GENERAL MEETING

At the annual general meeting of Jacobson Pharma Corporation Limited (the "**Company**") held on Tuesday, 11 August 2026 (the "**AGM**"), all the proposed resolutions as set out in the notice of the AGM dated 17 July 2026 (the "**AGM Notice**") were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	**Against**
1.	To receive, consider and approve the audited consolidated financial statements of the Company and the reports of the directors and the independent auditor for the year ended 31 March 2026.	1,668,632,310 (99.98%)	324,153 (0.02%)
2.	To declare a final dividend of HK4.75 cents per share for the year ended 31 March 2026.	1,668,956,463 (100.00%)	0 (0.00%)
3.	To re-elect Dr. Lam Kwing Tong, Alan (who has served for more than nine years) as an independent non-executive director of the Company.	1,668,000,583 (99.94%)	955,880 (0.06%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
4.	To re-elect Mr. Luk Ting Lung, Alan as an independent non-executive director of the Company.	1,668,512,463 (99.97%)	444,000 (0.03%)
5.	To authorise the board of directors of the Company (the "**Board**") to fix the respective directors' remuneration.	1,668,956,463 (100.00%)	0 (0.00%)
6.	To re-appoint KPMG as auditor until the conclusion of the next annual general meeting and to authorise the Board to fix their remuneration.	1,668,514,310 (99.97%)	442,153 (0.03%)
7.	To give a general mandate to the directors of the Company to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.*	1,668,956,463 (100.00%)	0 (0.00%)
8.	To give a general mandate to the directors of the Company to allot, issue and deal with additional shares of the Company (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.*	1,629,341,001 (97.63%)	39,615,462 (2.37%)
9.	To extend the general mandate granted to the directors of the Company to allot, issue and deal with additional shares (including any sale or transfer of treasury shares out of treasury) in the capital of the Company by the aggregate number of the shares repurchased by the Company.*	1,629,341,001 (97.63%)	39,615,462 (2.37%)

* *The full text of the resolutions is set out in the AGM Notice.*

Notes:

(a) As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 9, such resolutions were duly passed as ordinary resolutions.

(b) As at the date of the AGM, the total number of shares of the Company in issue was 2,000,221,000 shares.

(c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 2,000,221,000 shares. There were no repurchased shares pending cancellation or treasury shares held by the Company as at the date of the AGM.

(d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**").

(e) No shareholder of the Company (the "**Shareholder(s)**") was required under the Listing Rules to abstain from voting on the resolutions at the AGM.

(f) None of the Shareholders have stated their intention in the Company's circular dated 17 July 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.

(g) The Company's branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the poll at the AGM.

(h) All directors of the Company attended the AGM.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

Reference is made to the announcement of the Company dated 23 June 2026 regarding the retirement of Mr. Young Chun Man, Kenneth ("**Mr. Young**") as an independent non-executive director of the Company and also ceased to be the chairman of each of the audit committee and the nomination committee of the Company and a member of the remuneration committee of the Company at the conclusion of the AGM.

The Board hereby announces that Mr. Wong Tze Hang ("**Mr. Wong**") has been appointed as an independent non-executive director of the Company, the chairman of the audit committee of the Company and a member of the nomination committee of the Company, with effect from 11 August 2026 following the retirement of Mr. Young. The biographical details of Mr. Wong are set out as follows:

Mr. Wong, aged 63, has been appointed as an independent non-executive director of the Company, the chairman of the audit committee of the Company and a member of the nomination committee of the Company on 11 August 2026. Mr. Wong has over 35 years of experience in the finance and accounting field.

Mr. Wong was an executive director of Gold Peak Technology Group Limited (formerly known as Gold Peak Industries (Holdings) Limited, a company listed on the Main Board of the Stock Exchange, stock code: 40) from April 2019 to March 2024.

Mr. Wong obtained a bachelor of laws degree from the University of London, United Kingdom in August 2004. He has been a fellow member of the Hong Kong Institute of Certified Public Accountants since March 1999.

Save as disclosed above and as at the date of this announcement, Mr. Wong (i) has not previously held and does not hold any other positions with the Company and its subsidiaries (the "**Group**"); (ii) did not hold any other directorships in any public companies the securities of which are listed in Hong Kong or overseas in the last three years; and (iii) did not have any other major appointments and professional qualifications. As at the date of this announcement, save as disclosed above, Mr. Wong does not have any relationships with any other directors, senior management, or substantial or controlling shareholders of the Company, and he does not have any interests in the shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to an appointment letter entered into between Mr. Wong and the Company, Mr. Wong is entitled to receive a remuneration of HK$230,000 per annum (subject to review by the remuneration committee of the Company from time to time). Such remuneration is determined by reference to factors including his background, qualifications, experiences, duties and responsibilities within the Group, and the prevailing market conditions. According to the appointment letter entered into between Mr. Wong and the Company, Mr. Wong shall be appointed for an initial period of three years from the date of appointment. According to the Articles of Association of the Company, Mr. Wong will hold office until the first annual general meeting of the Company in 2027 (the "**2027 AGM**"), and shall then be eligible for re-election at the 2027 AGM. Thereafter, he will be subject to retirement by rotation at an annual general meeting of the Company in accordance with the Articles of Association of the Company.

Mr. Wong has confirmed: (a) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (b) save as disclosed above, he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (c) that there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters concerning the appointment of Mr. Wong that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its warmest welcome to Mr. Wong on his appointment.

The Board further announces that Dr. Lam Kwing Tong, Alan, an independent non-executive director of the Company, has resigned as a member of the nomination committee of the Company and Mr. Luk Ting Lung, Alan, an independent non-executive director of the Company, has been appointed as the chairman of the nomination committee of the Company and a member of the remuneration committee of the Company, with effect from 11 August 2026 following the retirement of Mr. Young.

By Order of the Board
Jacobson Pharma Corporation Limited
YU Chun Kau
Company Secretary

Hong Kong, 11 August 2026

As at the date of this announcement and after the conclusion of the AGM, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Luk Ting Lung, Alan and Mr. Wong Tze Hang as independent non-executive Directors.